Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley
CEO, Dr Jackie Fairley
Source: BioWorld
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Starpharma’s (SPL) VIRALEZE nasal spray will soon be sold and distributed by one of the U.K.’s pharmacies, LloydsPharmacy, which is part of the McKesson group
  • VIRALEZE is a broad-spectrum antiviral nasal spray which contains an active ingredient that has been shown to inactivate more than 99.9 per cent of SARS-CoV-2 the virus which causes COVID-19
  • Under the agreement with LloydsPharmacy, the nasal spray will be available online from next week and instore from next month
  • After VIRALEZE hits shelves in the UK, Starpharma intends to roll out the product across Europe
  • Shares last traded at $2.03

Starpharma’s (SPL) VIRALEZE nasal spray will soon be sold and distributed by one of the UK’s pharmacies, LloydsPharmacy.

VIRALEZE is a broad-spectrum antiviral nasal spray which contains an active ingredient that has been shown to inactivate more than 99.9 per cent of SARS-CoV-2 — the virus which causes COVID-19.

Under the agreement, the nasal spray will initially be available exclusively at LloydsPharmacy, with the product going online from next week and being stocked in-store from April.

“We are excited that VIRALEZE will be available from next week in the second largest pharmacy chain in the UK,” Starpharma CEO Dr Jackie Fairley.

“The LloydsPharmacy/McKesson team shares Starpharma’s enthusiasm and commitment to bring VIRALEZE antiviral nasal spray to U.K. consumers as they emerge from their latest lockdown. LloydsPharmacy represents an ideal partner for this product.”

LloydsPharmacy has around 1400 stores in the country and is part of the McKesson Europe, a pharmaceutical wholesale and retail pharmacy company in 13 European countries.

Head of eCommerce and Category Management at LloydsPharmacy John Acland said the company is excited to have the exclusive rights for VIRALEZE in the U.K.

“It is a highly innovative product with compelling customer benefits and is well supported by an impressive body of quality science and research.”

“We hope VIRALEZE will bring LloydsPharmacy customers added peace of mind and protection as we enter the next chapter of the pandemic and re-emerge back into work, school and social settings,” he added.

Following its U.K. launch, Starpharma intends to roll out the product across Europe.

Shares last traded at $2.03.

SPL by the numbers
More From The Market Herald

" Race Oncology (ASX:RAC) reports $1.8m in cash outflows

Race Oncology (ASX:RAC) reports $1.8 million in cash outflows
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…
Fiji Kava (ASZ:FIJ) - CEO and Managing Director, Dr Anthony Noble

" Fiji Kava (ASX:FIJ) hits quarterly revenue record

Fiji Kava (ASX:FIJ) has tabled a record quarterly revenue of $476,531 for the December quarter, up…